Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

The deal values OranoMed at €1.9bn, as Sanofi becomes the latest big pharmaceutical company to explore one of the most popular new areas of oncology. Radiopharmaceuticals, otherwise known as ...

PARIS--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an ...

Sanofi and the nuclear corporation Orano have agreed to coinvest in a new Orano subsidiary that will develop radioligands based on lead-212 α-emitting isotopes. Sanofi will invest about $325 ...

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight ...

Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their ...